Zheng L.-Y.,Fifth Central Hospital of Tianjin |
Zhang M.-H.,Fifth Central Hospital of Tianjin |
Xue J.-H.,Fifth Central Hospital of Tianjin |
Li Y.,Fifth Central Hospital of Tianjin |
And 4 more authors.
European Review for Medical and Pharmacological Sciences | Year: 2014
OBJECTIVE: Atrial fibrillation (AF) has been identified to contribute significantly to the morbidity and mortality of cardiovascular disease patients. The atrial structural remodeling is a hallmark of AF and the molecular mechanisms underlying this remain unclear. Hence the objective of the present study is to determine the role of angiotensin II (Ang- II)/Ang-II type 1 (AT1) receptor - STAT3 signaling pathway on - Atrial structural remodeling. MATERIALS AND METHODS: The method of this study involves incubation of atrial myocytes, with Ang-II, to increase the level of apoptosis expressions by Tunel assay and the expression of apoptosis related factors like caspase 3 and 8 release of cytochrome C from mitochondria to cytosol by western blot test after OGD pre-treatment. RESULTS: Atrial myocytes were shown to simulate the ischemia, hypoxia and atrial fibrillation. When incubated with Ang-II, (inhibited by losartan) the improvement was observed in the expression of caspase-3 and caspase-8. Ang-II also significantly promoted the transfer of cytochrome C levels from the mitochondria to the cytoplasm and this transfer was observed to be inhibited by losartan and WP1066. Ang-II incubation showed improved transcriptions of collagens and MMP expressions in atrial fibroblasts. In cultured atrial myocytes and fibroblasts, Ang-II induced tyrosine and serine phosphorylation of STAT3 showing interaction with MMP1 and MMP2 and DNA promoter sequences in atrial fibroblasts. The complete sequence was observed to have an affinity to be inhibited by losartan and WP1066. CONCLUSIONS: Ang-II/AT1 receptor/STAT3 is an important signaling pathway in the atrial structural remodeling, Ang-II enhances the apoptosis of atrial parenchyma and deposition of atrial ECM, which might contributes to atrial fibrillation.
Hou X.,First Hospital of Beijing University
Conference proceedings : ... Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Conference | Year: 2011
To study the changes of cerebral oxygenation and hemodynamics in normal neonates at 2-5 min post-birth and understand the effects of pregnancy-induced hypertension (PIH) upon cerebral oxygenation and hemodynamics in newborn neonates. The near infrared spectroscopy (NIRS) was employed to measure the absolute quantity of brain tissue oxygen saturation (rSO2) in newborn neonates and the changes of concentrations of deoxyhemoglobin (Hb) and oxygenation hemoglobin (HbO2) with time relative to initial values to further obtain the changes of total hemoglobin (tHb) and cerebral perfusion (denoted by HbD). In normal neonates at 2-5 min post-birth, rSO2 increased while tHb remained relatively stable and HbD increased. In neonates born of PIH mothers at 3-5 min post-birth, the changes of tHb were markedly higher than those in the normal infants, p<0.05; at 2-5 min post-birth, the changes were markedly lower than the normal term infants. We concluded that NIRS can detect the changes of cerebral oxygenation and blood flow in a non-invasive and effective way.
Liu X.,Central South University |
Huang W.,Central South University |
Leo S.,Central South University |
Li Y.,Central South University |
And 2 more authors.
Kidney and Blood Pressure Research | Year: 2014
Background/Aims: There is a strong correlation between non-dipping status and cardiovascular events in chronic kidney disease (CKD) patients. Our study is designed to identify the effect of evening administration of antihypertensive drugs to hypertensive CKD patients. Methods: A comprehensive search of Medline, Embase, the Chinese Biomedical Literature Database, Wanfang Data, Chinese National Knowledge Infrastructure, and the Cochrane Central Register of Controlled Trials was performed in July 2014. Concurrent controlled or crossover trials (including randomized and non-randomized experimental trials) designed to evaluate the effects of evening- versus morning-dosing hypertensive drug regimens on clinical outcomes in CKD patients with hypertension were included. All statistical analyses were performed using the RevMan software, which is available free from the Cochrane Collaboration. Results: Seven trials involving 1277 patients were identified, and the randomized controlled trials (RCTs) and non-randomized controlled trials (non-RCTs) were classified into two groups. Taking at least one blood pressure-lowering medication at bedtime was not shown to reduce total death (P=0.056) or cardiovascular death (P=0.059) but was shown to reduce total events (P<0.001) and major cardiovascular events (P<0.001) in both RCTs and non-RCTs. Compared with a morning dosing regimen, taking antihypertensive drug in the evening significantly lowered nighttime systolic blood pressure (SBP) (P<0.0001) and diastolic blood pressure (P<0.05) in patients in the RCTs but did not affect blood pressure in patients in the non-RCTs (P<0.05). There is limited evidence from one non-RCT that taking an antihypertensive drug (benazepril 10 mg) in the evening did not increase adverse events (P=0.72) or withdrawals due to adverse events (P=0.64). Conclusions: A regimen of antihypertensive drugs in the evening should be considered for CKD patients with hypertension to lower nighttime blood pressure and help prevent total events and cardiovascular mortality. More studies are needed to verify the results of this study. © 2015 S. Karger AG, Basel.
Zhou W.-H.,Fudan University |
Cheng G.-Q.,Fudan University |
Shao X.-M.,Fudan University |
Liu X.-Z.,Guangxi Maternity and Infant Health Hospital |
And 7 more authors.
Journal of Pediatrics | Year: 2010
Objective: To investigate the efficacy and safety of selective head cooling with mild systemic hypothermia in hypoxic-ischemic encephalopathy (HIE) in newborn infants. Study design: Infants with HIE were randomly assigned to the selective head cooling or control group. Selective head cooling was initiated within 6 hours after birth to a nasopharyngeal temperature of 34° ± 0.2°C and rectal temperature of 34.5° to 35.0°C for 72 hours. Rectal temperature was maintained at 36.0° to 37.5°C in the control group. Neurodevelopmental outcome was assessed at 18 months of age. The primary outcome was a combined end point of death and severe disability. Results: One hundred ninety-four infants were available for analysis (100 and 94 infants in the selective head cooling and control group, respectively). For the selective head cooling and control groups, respectively, the combined outcome of death and severe disability was 31% and 49% (OR: 0.47; 95% CI: 0.26-0.84; P = .01), the mortality rate was 20% and 29% (OR:0.62; 95% CI: 0.32-1.20; P = .16), and the severe disability rate was 14% (11/80) and 28% (19/67) (OR: 0.40; 95% CI: 0.17-0.92; P = .01). Conclusions: Selective head cooling combined with mild systemic hypothermia for 72 hours may significantly decrease the combined outcome of severe disability and death, as well as severe disability. © 2010 Mosby Inc. All rights reserved.
Han Y.,Shenyang Northern Hospital |
Zhu G.,Wuhan Asia Heart Hospital |
Han L.,Cangzhou Central Hospital |
Hou F.,ChangChun Central Hospital |
And 19 more authors.
Journal of the American College of Cardiology | Year: 2014
Objectives This study sought to evaluate the safety and efficacy of rosuvastatin in preventing contrast-induced acute kidney injury (CI-AKI) in patients with diabetes mellitus (DM) and chronic kidney disease (CKD). Background CI-AKI is an important complication after contrast medium injection. While small studies have shown positive results with statin therapy, the role of statin therapy in prevention of CI-AKI remains unknown. Methods We randomized 2,998 patients with type 2 DM and concomitant CKD who were undergoing coronary/peripheral arterial angiography with or without percutaneous intervention to receive rosuvastatin, 10 mg/day (n = 1,498), for 5 days (2 days before, and 3 days after procedure) or standard-of-care (n = 1,500). Patients' renal function was assessed at baseline, 48 h, and 72 h after exposure to contrast medium. The primary endpoint of the study was the development of CI-AKI, which was defined as an increase in serum creatinine concentration ≥0.5 mg/dl (44.2 μmol/l) or 0.25% above baseline at 72 h after exposure to contrast medium. Results Patients randomized to the rosuvastatin group had a significantly lower incidence of CI-AKI than controls (2.3% vs. 3.9%, respectively; p = 0.01). During 30 days' follow-up, the rate of worsening heart failure was significantly lower in the patients treated with rosuvastatin than that in the control group (2.6% vs. 4.3%, respectively; p = 0.02). Conclusions Rosuvastatin significantly reduced the risk of CI-AKI in patients with DM and CKD undergoing arterial contrast medium injection. (Rosuvastatin Prevent Contrast Induced Acute Kidney Injury in Patients With Diabetes [TRACK-D]; NCT00786136).